The role of vascular endothelial growth factor in major depression

Bun Hee Lee, Yong Ku Kim

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Vascular endothelial growth factor (VEGF) is a potent angiogenic factor under physiological and pathological conditions, including tumor angiogenesis. Recently, the effects of VEGF on neurons have been reported. VEGF and its high-affinity tyrosine kinase receptors, VEGFR1 and VEGFR2, are expressed in specific brain regions. In addition, VEGF has been suggested to play an important role in the cross-talk between endothelial cells and neuronal progenitors in the hippocampus, indicating that VEGF may stimulate hippocampal neurogenesis. Neurotrophic factors and neurogenesis are associated with the development of major depression and play essential roles in mediating the therapeutic response to antidepressants. Several animal studies have shown that chronic stress decreased the expression of VEGF and VEGFR2 in granular cells. There is also evidence suggesting that antidepressant treatment-induced neurogenesis requires VEGF signaling through VEGFR2. Clinical studies, however, have been controversial. Some researchers reported no significant difference in serum/plasma VEGF level between patients with major depressive disorder (MDD) and healthy controls, whereas others found that VEGF level was significantly higher in MDD patients than in controls. Furthermore, psycho-oncology studies have shown that higher VEGF levels in serum and tumor cells are associated with depressive states in patients with tumors. Consistently, noradrenaline, a stress hormone, significantly enhanced VEGF production in various tumor cells in vitro, and this effect was blocked by beta-blockers. These findings suggest that stress or stress-related mediators promote VEGF production in tumors. VEGF in the central nervous system (CNS), however, showed a distinct pattern of changes compared to serum (somatic) VEGF. Chronic stress is known to decrease the production and signaling of VEGF in the CNS, while stress increases the production of VEGF by somatic tumor cells. The mechanism responsible for the changes in VEGF levels remains elusive and needs further investigation.

Original languageEnglish
Title of host publicationVascular Endothelial Growth Factor (VEGF)
Subtitle of host publicationBiology, Regulation and Clinical Significance
PublisherNova Science Publishers, Inc.
Pages201-208
Number of pages8
ISBN (Print)9781626186552
Publication statusPublished - 2013 Dec 1

Fingerprint

Vascular Endothelial Growth Factor A
Depression
Tumors
Neurogenesis
Neoplasms
Cells
Major Depressive Disorder
Neurology
Antidepressive Agents
Central Nervous System
Serum
Oncology
Angiogenesis Inducing Agents
Endothelial cells
Nerve Growth Factors
Receptor Protein-Tyrosine Kinases
Neurons
Hippocampus
Brain
Norepinephrine

Keywords

  • Depression
  • Neurogenesis
  • Stress
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Lee, B. H., & Kim, Y. K. (2013). The role of vascular endothelial growth factor in major depression. In Vascular Endothelial Growth Factor (VEGF): Biology, Regulation and Clinical Significance (pp. 201-208). Nova Science Publishers, Inc..

The role of vascular endothelial growth factor in major depression. / Lee, Bun Hee; Kim, Yong Ku.

Vascular Endothelial Growth Factor (VEGF): Biology, Regulation and Clinical Significance. Nova Science Publishers, Inc., 2013. p. 201-208.

Research output: Chapter in Book/Report/Conference proceedingChapter

Lee, BH & Kim, YK 2013, The role of vascular endothelial growth factor in major depression. in Vascular Endothelial Growth Factor (VEGF): Biology, Regulation and Clinical Significance. Nova Science Publishers, Inc., pp. 201-208.
Lee BH, Kim YK. The role of vascular endothelial growth factor in major depression. In Vascular Endothelial Growth Factor (VEGF): Biology, Regulation and Clinical Significance. Nova Science Publishers, Inc. 2013. p. 201-208
Lee, Bun Hee ; Kim, Yong Ku. / The role of vascular endothelial growth factor in major depression. Vascular Endothelial Growth Factor (VEGF): Biology, Regulation and Clinical Significance. Nova Science Publishers, Inc., 2013. pp. 201-208
@inbook{a2fc91be0b6946dba7338c4e227ffa1e,
title = "The role of vascular endothelial growth factor in major depression",
abstract = "Vascular endothelial growth factor (VEGF) is a potent angiogenic factor under physiological and pathological conditions, including tumor angiogenesis. Recently, the effects of VEGF on neurons have been reported. VEGF and its high-affinity tyrosine kinase receptors, VEGFR1 and VEGFR2, are expressed in specific brain regions. In addition, VEGF has been suggested to play an important role in the cross-talk between endothelial cells and neuronal progenitors in the hippocampus, indicating that VEGF may stimulate hippocampal neurogenesis. Neurotrophic factors and neurogenesis are associated with the development of major depression and play essential roles in mediating the therapeutic response to antidepressants. Several animal studies have shown that chronic stress decreased the expression of VEGF and VEGFR2 in granular cells. There is also evidence suggesting that antidepressant treatment-induced neurogenesis requires VEGF signaling through VEGFR2. Clinical studies, however, have been controversial. Some researchers reported no significant difference in serum/plasma VEGF level between patients with major depressive disorder (MDD) and healthy controls, whereas others found that VEGF level was significantly higher in MDD patients than in controls. Furthermore, psycho-oncology studies have shown that higher VEGF levels in serum and tumor cells are associated with depressive states in patients with tumors. Consistently, noradrenaline, a stress hormone, significantly enhanced VEGF production in various tumor cells in vitro, and this effect was blocked by beta-blockers. These findings suggest that stress or stress-related mediators promote VEGF production in tumors. VEGF in the central nervous system (CNS), however, showed a distinct pattern of changes compared to serum (somatic) VEGF. Chronic stress is known to decrease the production and signaling of VEGF in the CNS, while stress increases the production of VEGF by somatic tumor cells. The mechanism responsible for the changes in VEGF levels remains elusive and needs further investigation.",
keywords = "Depression, Neurogenesis, Stress, Vascular endothelial growth factor",
author = "Lee, {Bun Hee} and Kim, {Yong Ku}",
year = "2013",
month = "12",
day = "1",
language = "English",
isbn = "9781626186552",
pages = "201--208",
booktitle = "Vascular Endothelial Growth Factor (VEGF)",
publisher = "Nova Science Publishers, Inc.",

}

TY - CHAP

T1 - The role of vascular endothelial growth factor in major depression

AU - Lee, Bun Hee

AU - Kim, Yong Ku

PY - 2013/12/1

Y1 - 2013/12/1

N2 - Vascular endothelial growth factor (VEGF) is a potent angiogenic factor under physiological and pathological conditions, including tumor angiogenesis. Recently, the effects of VEGF on neurons have been reported. VEGF and its high-affinity tyrosine kinase receptors, VEGFR1 and VEGFR2, are expressed in specific brain regions. In addition, VEGF has been suggested to play an important role in the cross-talk between endothelial cells and neuronal progenitors in the hippocampus, indicating that VEGF may stimulate hippocampal neurogenesis. Neurotrophic factors and neurogenesis are associated with the development of major depression and play essential roles in mediating the therapeutic response to antidepressants. Several animal studies have shown that chronic stress decreased the expression of VEGF and VEGFR2 in granular cells. There is also evidence suggesting that antidepressant treatment-induced neurogenesis requires VEGF signaling through VEGFR2. Clinical studies, however, have been controversial. Some researchers reported no significant difference in serum/plasma VEGF level between patients with major depressive disorder (MDD) and healthy controls, whereas others found that VEGF level was significantly higher in MDD patients than in controls. Furthermore, psycho-oncology studies have shown that higher VEGF levels in serum and tumor cells are associated with depressive states in patients with tumors. Consistently, noradrenaline, a stress hormone, significantly enhanced VEGF production in various tumor cells in vitro, and this effect was blocked by beta-blockers. These findings suggest that stress or stress-related mediators promote VEGF production in tumors. VEGF in the central nervous system (CNS), however, showed a distinct pattern of changes compared to serum (somatic) VEGF. Chronic stress is known to decrease the production and signaling of VEGF in the CNS, while stress increases the production of VEGF by somatic tumor cells. The mechanism responsible for the changes in VEGF levels remains elusive and needs further investigation.

AB - Vascular endothelial growth factor (VEGF) is a potent angiogenic factor under physiological and pathological conditions, including tumor angiogenesis. Recently, the effects of VEGF on neurons have been reported. VEGF and its high-affinity tyrosine kinase receptors, VEGFR1 and VEGFR2, are expressed in specific brain regions. In addition, VEGF has been suggested to play an important role in the cross-talk between endothelial cells and neuronal progenitors in the hippocampus, indicating that VEGF may stimulate hippocampal neurogenesis. Neurotrophic factors and neurogenesis are associated with the development of major depression and play essential roles in mediating the therapeutic response to antidepressants. Several animal studies have shown that chronic stress decreased the expression of VEGF and VEGFR2 in granular cells. There is also evidence suggesting that antidepressant treatment-induced neurogenesis requires VEGF signaling through VEGFR2. Clinical studies, however, have been controversial. Some researchers reported no significant difference in serum/plasma VEGF level between patients with major depressive disorder (MDD) and healthy controls, whereas others found that VEGF level was significantly higher in MDD patients than in controls. Furthermore, psycho-oncology studies have shown that higher VEGF levels in serum and tumor cells are associated with depressive states in patients with tumors. Consistently, noradrenaline, a stress hormone, significantly enhanced VEGF production in various tumor cells in vitro, and this effect was blocked by beta-blockers. These findings suggest that stress or stress-related mediators promote VEGF production in tumors. VEGF in the central nervous system (CNS), however, showed a distinct pattern of changes compared to serum (somatic) VEGF. Chronic stress is known to decrease the production and signaling of VEGF in the CNS, while stress increases the production of VEGF by somatic tumor cells. The mechanism responsible for the changes in VEGF levels remains elusive and needs further investigation.

KW - Depression

KW - Neurogenesis

KW - Stress

KW - Vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=84892108604&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892108604&partnerID=8YFLogxK

M3 - Chapter

AN - SCOPUS:84892108604

SN - 9781626186552

SP - 201

EP - 208

BT - Vascular Endothelial Growth Factor (VEGF)

PB - Nova Science Publishers, Inc.

ER -